Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications

Gaetano Aurilio,Alessia Cimadamore,Roberta Mazzucchelli,Antonio Lopez-Beltran,Elena Verri,Marina Scarpelli,Francesco Massari,Liang Cheng,Matteo Santoni,Rodolfo Montironi

DOI: https://doi.org/10.3390/cells9122653

IF: 6

2020-12-10

Cells

Abstract:Around 80–90% of prostate cancer (PCa) cases are dependent on androgens at initial diagnosis; hence, androgen ablation therapy directed toward a reduction in serum androgens and the inhibition of androgen receptor (AR) is generally the first therapy adopted. However, the patient’s response to androgen ablation therapy is variable, and 20–30% of PCa cases become castration resistant (CRPCa). Several mechanisms can guide treatment resistance to anti-AR molecules. In this regard, AR-dependent and -independent resistance mechanisms can be distinguished within the AR pathway. In this article, we investigate the multitude of AR signaling aspects, encompassing the biological structure of AR, current AR-targeted therapies, mechanisms driving resistance to AR, and AR crosstalk with other pathways, in an attempt to provide a comprehensive review for the PCa research community. We also summarize the new anti-AR drugs approved in non-metastatic castration-resistant PCa, in the castration-sensitive setting, and combination therapies with other drugs.

cell biology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the mechanism by which prostate cancer (PCa) develops resistance to androgen ablation therapy (AAT). Specifically, the paper focuses on the role of the androgen receptor (AR) signaling pathway in the development of prostate cancer, especially in the case where patients have different responses to androgen ablation therapy. Approximately 20 - 30% of prostate cancer cases will develop into castration - resistant prostate cancer (CRPCa). The paper explores multiple mechanisms that lead to this resistance, including AR - dependent and AR - independent mechanisms, and discusses the interactions between AR and other signaling pathways. In addition, the paper also summarizes new anti - AR drugs for non - metastatic castration - resistant prostate cancer, as well as combination therapies in a castration - sensitive environment. Through these discussions, the paper aims to provide a comprehensive literature review for the prostate cancer research community to better understand and address the treatment challenges of prostate cancer.